Vimarsana
Biggest News Aggregation in the World

Page 11 - Acticor Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acticor Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acticor Biotech Today - Breaking & Trending Today

ACTICOR BIOTECH: Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development - Vimarsana News

ACTICOR BIOTECH: Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development

Successful IPO on Euronext Growth in Paris Cash position of €11.3 million at 31 December 2021 Promising clinical results with the continuing development of glenzocimab for use in stroke Regulatory

ACTICOR BIOTECH: Acticor Biotech Announces the Appointment of Corinne Le Goff to the Board of Directors as an Independent Director - Vimarsana News

ACTICOR BIOTECH: Acticor Biotech Announces the Appointment of Corinne Le Goff to the Board of Directors as an Independent Director

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company specialized in developing innovative treatments for cardiovascular emergencies

Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million. - Vimarsana News

Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million.

Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million. Brussels, Belgium, 15 February 2022 – Newton Biocapital (“Newton”), a life sciences investor, announces the launch of its new fund (NBC II). As with NBC I, NBC II w...

Acticor Biotech: Results of the Phase 2 GARDEN Study in COVID-19-Related Acute Respiratory Distress Syndrome - Vimarsana News

Acticor Biotech: Results of the Phase 2 GARDEN Study in COVID-19-Related Acute Respiratory Distress Syndrome

Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announced today the results of

ACTICOR BIOTECH: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Vimarsana News

ACTICOR BIOTECH: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies